To achieve the goal of clinical research, i.e., the more effective diagnosis and treatment of patients with schizophrenia, the main need is to confirm the basic link between clinical symptoms and the effects of antipsychotic treatment in relation to reelin downstream signaling molecules, identifying their roles as specific markers of psychosis [29,115,116]. This evidence concerns the gene RELN and schizophrenia.